Freshfields advises Shanghai Henlius Biotech, Inc. on its proposed privatisation
Global law firm Freshfields Bruckhaus Deringer (‘Freshfields’) is advising Shanghai Henlius Biotech, Inc. (‘Henlius’), a biopharmaceutical company listed on the Hong Kong Stock Exchange (Stock Code: 2696), on its proposed privatisation by Shanghai Fosun New Medicine Research Company Limited by way of merger by absorption.
The transaction is subject to various conditions, including amongst others independent shareholder approvals.
The Freshfields team was led by partners Edward Freeman, Grace Huang and David Yi, supported by senior associate Kelly Huang, and associate Haohan Li.
The Freshfields team advising on the transaction was led by:
